Daiichi Sankyo

OTC:DSNKYPharma

Tokyo, Japan, Japan · Est. 2005 · 16,000 employees

Daiichi Sankyo is a Japanese pharmaceutical company focused on developing innovative medicines in oncology, cardiovascular, and immunological disease areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

420

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

25 drugs in development

Phase 32

Phase 215

Phase 18

Preclinical6

By Therapeutic Area

top 6

Oncology

2269%

Nephrology

26%

Neurology

26%

Musculoskeletal

13%

Gastroenterology

13%

Rare Disease

13%

R&D Momentum

74/100

Pipeline Velocity

47/100

Trial Completion Rate

87/100

Pipeline Concentration

49/100

Pipeline Freshness

66/100

Strategic Signals

↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 10, 2026

Recruiting

Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study

Jul 10, 2026

Recruiting

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

Jul 10, 2026

Recruiting

A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Jul 7, 2026

Recruiting

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Jul 3, 2026

Recruiting

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Jul 3, 2026

Recruiting

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)

Jul 3, 2026

Recruiting

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

Jul 3, 2026

Active, not recruiting

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Jul 2, 2026

Recruiting

A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors

Jul 2, 2026

Recruiting

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

Details

Company Info

Company Overview

$50.0B

Mkt Cap

$9.0B

Revenue

—

Cash

CEOMasao Uchibori

Founded2005

Employees16,000

HQTokyo, Japan, Japan

ExchangeOTC:DSNKY

Websitedaiichisankyo.com

LinkedInCompany Page

Therapeutic Focus

OncologyCardiovascularMusculoskeletalOtherNeurologyNephrologyHematologyInfectious DiseaseGastroenterologyMetabolic & EndocrineRespiratoryImmunologyOphthalmologyRare Disease

Patent Expirations

13 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Vanflyta4 patentsMar 16, 2027 SavaysaApr 18, 2027 Turalio3 patentsNov 21, 2027 SavaysaMar 28, 2028 TuralioApr 19, 2028 VanflytaSep 26, 2028 Vanflyta2 patentsAug 15, 2029 Vanflyta2 patentsMar 23, 2030

5 more

VanflytaFeb 26, 2031 Turalio2 patentsMay 4, 2033 VanflytaSep 30, 2033 Turalio3 patentsMay 5, 2036 Turalio3 patentsJul 24, 2038

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Musculoskeletal(1 drug)

—

Musculoskeletal(1 drug)

Nephrology(2 drugs)

—

Nephrology(2 drugs)

Neurology(2 drugs)

—

Neurology(2 drugs)

Oncology(22 drugs)

—

Oncology(22 drugs)

Rare Disease(1 drug)

—

Rare Disease(1 drug)

Unknown / Other(3 drugs)

—

Unknown / Other(3 drugs)

Regulatory

Regulatory Timeline

20151 event

FDAJan 8

Savaysa — SAVAYSA

Application NDA206316 (NDA)

20191 event

FDADec 20

ENHERTU — ENHERTU

Application BLA761139 (BLA)

20221 event

FDAOct 14

Turalio — TURALIO

Application NDA211810 (NDA)

20231 event

FDAJul 20

Vanflyta — VANFLYTA

Application NDA216993 (NDA)

20251 event

FDAJan 17

DATROWAY — DATROWAY

Application BLA761394 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)